A Potential Important Role of Skeletal Muscle in Human Counterregulation of Hypoglycemia

• Published in: The journal of clinical endocrinology and metabolism Vol. 90; no. 11; pp. 6244 - 6250
• Main Authors: Meyer, Christian, Saar, Petra, Soydan, Nedim, Eckhard, Michael, Bretzel, Reinhard G, Gerich, John, Linn, Thomas
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Endocrine Society 01.11.2005; Copyright by The Endocrine Society
• Subjects: Adult; Alanine - metabolism; Biological and medical sciences; Blood Glucose - analysis; Endocrinopathies; Female; Forearm - blood supply; Fundamental and applied biological sciences. Psychology; Gluconeogenesis; Glucose - metabolism; Glycogenolysis; Humans; Hypoglycemia - metabolism; Lactic Acid - metabolism; Male; Medical sciences; Muscle, Skeletal - metabolism; Vertebrates: endocrinology; Human; Metabolic diseases; Hypoglycemia; Striated muscle; Endocrinology
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.2005-0225

Context: During hypoglycemia, systemic glucose uptake (SGU) decreases and endogenous glucose release (EGR) increases. Skeletal muscle appears to be primarily responsible for the reduced SGU and may be important for the increased EGR by providing lactate for gluconeogenesis (GN). Objective: The objective of the study was to test the hypothesis that reduced muscle glucose uptake and increased muscle lactate release both make major contributions to glucose counterregulation using systemic isotopic techniques in combination with forearm net balance measurements. Setting: The study was conducted at the University of Giessen Clinical Research Center. Participants: Nine healthy volunteers participated in the study. Intervention: A 2-h hyperinsulinemic euglycemic clamp (blood glucose ∼ 4.4 mm) was followed by a 90-min hypoglycemic clamp (blood glucose ∼ 2.6 mm). Results: Compared with the euglycemic clamp, SGU decreased (21.0 ± 2.0 vs. 29.6 ± 1.8 μmol·kg body weight−1·min−1; P < 0.001), whereas EGR (11.2 ± 1.7 vs. 4.9 ± 1.3 μmol·kg body weight−1 ·min−1; P < 0.003), arterial lactate concentrations (1051 ± 162 vs. 907 ± 115 μm; P < 0.02), systemic lactate release (23.5 ± 0.9 vs. 17.1 ± 0.9 μmol·kg body weight−1·min−1; P < 0.001), and lactate GN (4.50 ± 0.60 vs. 2.74 ± 0.30 μmol·kg body weight−1·min−1; P < 0.02) increased during hypoglycemia; the proportion of lactate used for GN remained unchanged (38 ± 4 vs. 32 ± 3%; P = 0.27). Whole-body muscle glucose uptake decreased approximately 50% during hypoglycemia (6.4 ± 1.9 vs. 13.6 ± 2.9 μmol·kg body weight−1·min−1; P < 0.001), which accounted for approximately 85% of the reduction of SGU. Whole-body muscle lactate release increased 6.6 ± 1.6 μmol·kg body weight−1· min−1 (P < 0.01), which could have accounted for all the increase in systemic lactate release and, considering the proportion of lactate used for GN, contributed 1.4 ± 0.4 μmol·kg body weight−1·min−1 (∼25%) to the increase in EGR. Conclusions: Reduced muscle glucose uptake and increased muscle lactate release both make major contributions to glucose counterregulation in humans.